Abbott Vascular

3200 Lakeside Dr.

Santa Clara, CA 95054

USA

Phone:

(408) 845-3000

www.abbottvascular.com

Product Categories:

Embolic Protection Devices, Stents, Stents Drug Eluting, Vascular Closure Devices, Stents Carotid, Stents Peripheral, Stents Bare Metal

Related Content

News | Structural Heart Occluders | February 13, 2019

Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder

Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's...

News | Heart Valve Technology | January 28, 2019

First Tendyne Transcatheter Mitral Valve Implanted in New York

Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter...

Technology | Ablation Systems | January 21, 2019

FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled

Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...

News | Structural Heart Occluders | January 16, 2019

FDA Approves Abbott's Amplatzer Piccolo Occluder

Abbott announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder to treat patent...

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018

FDA Clears HeartMate 3 for Heart Failure Patients Not Eligible for Transplant

October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S

Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward.

Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor

The Next Step in Bioresorbable Stent Technologies

Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology